JAMA Oncology

@jamaoncology.com

845 Followers 59 Following

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMAOncology.com

JAMA Oncology article: 'Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review. A Systematic Review and Meta-Analysis.' Authors: Lis V. Ravani, Z. Bagheri, et al.
JAMA Oncology study: Atezolizumab maintenance for ES-SCLC. 68 patients randomized. Kaplan-Meier plot shows Atezolizumab only arm (median OS 13.4 mo) had better survival than Atezolizumab+TRT arm (6.7 mo). Recruitment ended due to adverse events in TRT arm.
RCT: Durvalumab + Chemo for advanced biliary tract cancer. 685 participants (median age 64) were randomized. Findings show Durvalumab + GemCis (341) significantly improved OS vs. Placebo + GemCis (344). HR 0.75. Graph shows survival curves.
JAMA Oncology article titled "Prospective Genomic Profiling of Consecutive Meningiomas" by Minh P. Nguyen, Kanish Mirchia, Brooke C. Braman, et al. Published online April 9, 2026. Includes navigation, author affiliations, article info, and share icons.
Figure 2. Bar graphs display outcomes for 5 patients after starting PARP inhibitors. Timelines mark events like PARP discontinuation, MDS/AML diagnosis, & death over several years. Most patients experienced an event, often within 5-10 years post-treatment.
Cumulative incidence graph over 9 years. Y-axis: Cumulative incidence per 100,000 persons (0-60). X-axis: Years after index event (0-9). The 'Unvaccinated' line (orange) consistently shows a higher incidence, rising to nearly 50. The 'Vaccinated' line (dark) shows a lower incidence, rising to almost 40.
Stacked bar chart: Risk of bias. Most categories (participation, attrition, prognostic factor measurement, outcome measurement, statistical analysis) are nearly all low risk. Confounding shows ~30% low, ~65% moderate, ~5% high risk. Overall: ~90% low, ~10% moderate. Legend: Low, Moderate, High risk of bias.
Bar graphs illustrating Tumor-Infiltrating Clonal Hematopoiesis (TI-CH) prevalence across CHIP driver genes & tumor types. TET2 is the most common CHIP driver variant. TI-CH-negative disease predominates over TI-CH-positive. Colon & rectum show the highest TI-CH variant distribution.
Figure 2. Distribution of SPM Entities, a horizontal bar chart showing Total SPMs by Cancer type (y-axis) vs. SPM events (x-axis, 0-14). Nonmelanoma skin cancer has the highest SPM events (approx. 9), followed by MDS and Unknown (approx. 4 each).
Figure 4. Bar graph showing percentage changes from baseline across Urinary, Bowel, Hormonal, Sexual, and Overall satisfaction domains of the Expanded Prostate Cancer Index Composite. Changes are classified as No, Little, Moderate, or Substantial. Most domains show high 'No change' percentages.
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing "with" vs. "without chemotherapy" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
Sagittal (A) and coronal (B) MRI brain scans show thickening of the pituitary stalk (arrowheads, 3.92mm). This image is from a JAMA Oncology article: 'Hypernatremia and Polyuria in a Patient With Metastatic Breast Cancer,' which also includes a 'What is your diagnosis?' section.
Schematic of Stage-Gated MRI interpretation shows two stages. Top row (positive findings): T2WI, DWI (high b), DWI (ADC map), and T2WI (sagittal plane) scans, all with pink arrows pointing to lesions. Bottom row (negative findings): T2WI & DWI (high b) scans, leading to 'Not reviewed'.
Protocol for low-risk gestational trophoblastic tumors (FIGO score ≤6): Curative treatment with 8-day Methotrexate and Avelumab until hCG normalization. Followed by 3 consolidation cycles of each drug, then a 3-year hCG monitoring follow-up: weekly, bi-weekly, monthly, then quarterly.
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing "with" vs. "without chemotherapy" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
Kaplan-Meier survival curves show overall survival for EOCRC patients with/without treatment delay across 4 graphs: general, localized, regional, metastatic. Treatment delay consistently leads to lower survival (P<.001-.047) over 72 months. Y-axis: Overall survival %.
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing "with" vs. "without chemotherapy" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
Two Kaplan-Meier curves. Top: Overall survival, showing Serplulimab+chemotherapy (orange) above Placebo+chemotherapy (teal) [HR 0.60, P<.001]. Bottom: Progression-free survival, with Serplulimab+chemotherapy clearly outperforming Placebo+chemotherapy [HR 0.47, P<.001].
JAMA Oncology Research Letter: "Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial." Authors: Chengshui Chen, Xinyu Liang, Zheng Peng et al. Published Online: March 5, 2026. doi:10.1001/jamaoncol.2026.0136.
Kaplan-Meier curves compare Chemoimmunotherapy (orange) vs PD-(L)1 inhibitor monotherapy (blue) for overall (A) and progression-free (B) survival. Chemoimmunotherapy shows higher survival probabilities in both graphs. HR values are 0.74 (A) and 0.67 (B), P<.001 for both.
JAMA study: Adjuvant nivolumab was not associated with improved disease-free survival in resected NSCLC patients without EGFR and ALK alterations. 935 patients randomized (466 nivolumab, 469 observation). Median disease-free survival: Nivolumab 71.3 mos (overall), Observation 68.8 mos (overall).
RCT: Fovinaciclib for Advanced Breast Cancer. A trial with 417 women randomized Fovinaciclib vs. placebo. Fovinaciclib significantly improved progression-free survival (PFS) compared to placebo, shown by a Kaplan-Meier graph (HR 0.55, 95% CI 0.38-0.77).
Sankey plots from the WISDOM Study show breast screening assignments by age group. Panel A (40-49 y) & B (50-74 y) illustrate the flow from BCSC model to BCSC-PRS model to Actual assignment. Node colors represent high-risk, annual, biennial mammography, and no/stop screening.
JAMA Oncology: Brief Report on Outcomes of Older Adults with Advanced Cancer preferring Quality of Life vs Prolonging Survival, a secondary analysis of the GAP70+ Clinical Trial. Authors: Richardson, Wang, Flannery et al. Published March 5, 2026.
Two line graphs show the estimated probability of Suicidal Self-Directed Violence (SSDV) over time for various cancer types, separated by stage. Both graphs indicate an increasing SSDV probability with time, with CNS, Pancreas, and Head/neck cancers showing consistently higher rates.
Diagram shows two ctDNA MRD assays. A) Tissue-informed: Cancer patient, biopsy, individualized assay design from tumor alterations, cfDNA extraction & ctDNA detection from plasma, results. B) Tissue-agnostic: Cancer patient, cfDNA extraction from plasma, computational methods identify ctDNA, results.
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing "with" vs. "without chemotherapy" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
Kaplan-Meier analysis of androgen deprivation therapy-free survival displays survival rates over 60 months for HDR-BT, sRP, SBRT, Cryotherapy, HIFU, and LDR-BT, with corresponding 'number at risk' data listed below the graph.
JAMA Oncology editorial: "Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation" by Asona Lui, MD, PhD@1; and Charles R. Thomas Jr, MD@2,3. Published online March 26, 2026.
JAMA Oncology brief report: 'Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous'. Authors: Andrew J. Vickers, PhD@1; Matthew Cooperberg, MD@2; Christian P. Pavlovich, MD@3; et al. Published online May 21, 2026.
JAMA Oncology Kaplan-Meier survival plot shows survival percentages from 0 to 100 versus follow-up period in months from 0 to 132 for LRFS, PFS, DSS, and OS. The number at risk is listed for each time. Published online May 16, 2026.
JAMA Oncology brief report: "Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous." Authors: Andrew J. Vickers, PhD, Matthew Cooperberg, MD, Christian P. Pavlovich, MD, et al. Published online May 21, 2026.
Kaplan-Meier estimates of survival. Top graph shows overall survival, with IP median @number and PS median @number. Bottom graph shows progression-free survival, IP median @number and PS median @number. X axis: Months since randomization.
Heat map showing percentages of early-stage lung cancer cases in the US from 2003-2022, broken down by age groups (40-44 to ≥90). Color intensity indicates percentage, ranging from 10% to 34%. Older age groups have more early stage detection over time.
JAMA Oncology Kaplan-Meier survival plot shows survival percentages from 0 to 100 versus follow-up period in months from 0 to 132 for LRFS, PFS, DSS, and OS. The number at risk is listed for each time. Published online May 16, 2026.
A JAMA Oncology article titled "Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults" by Adam H. Fox, et al. Published online May 7, 2026. DOI: 10.1001/jamaoncol.2026.1080.
A research letter from JAMA Oncology titled "Healthy Lifestyle Advice and Practice Among Cancer Survivors in the US" by Chao Cao, Kathryn H. Schmitz, Edward L. Giovannucci, et al. Published online April 30, 2026.
JAMA Oncology RCT: Tiragolumab plus atezolizumab & chemotherapy for advanced nonsquamous non-small cell lung cancer. Population: 353 male, 189 female, mean age 63.6. Intervention: 542 patients randomized. Findings: No statistically significant differences.
JAMA Oncology Research Letter: "Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib, A Secondary Analysis of a Nonrandomized Clinical Trial" by Kim A. Reiss et al. Published Online: April 30, 2026.
Image shows A) A pigmented skin lesion on a torso and B) contrast-enhancing lesions in the spine area, displayed in black and white from an MRI.
Kaplan-Meier and cumulative incidence plots for Adult T-Cell Leukemia/Lymphoma (ATLL). A and B show survival by race/ethnicity and cancer site, respectively. C and D show cumulative death incidence by race/ethnicity and cancer site.
Kaplan-Meier analysis of androgen deprivation therapy-free survival, time in months vs androgen deprivation therapy free survival. Various therapies are plotted: HDR-BT, sRP, SBRT, Cryotherapy, HIFU, LDR-BT(single study).
JAMA Oncology RCT: Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Population: 353 Male, 189 Female. Intervention: 542 patients randomized. Findings: no significant survival differences.
Information graphic titled "Taking care of your mouth during cancer treatment." Text describes mouth problems, like mouth sores and dry mouth, which may occur with cancer treatment. It offers dental care advice for before, during, and after treatment.
Two graphs show cumulative incidence of progression from smoldering multiple myeloma. Graph A shows high vs not high risk based on AQUILA trial criteria, with high risk rising faster. Graph B shows high, intermediate and low risk for 2/20/2020 model risk groups.
Figure 2 shows bar plots of model performance across ancestry and specimen sites. Graph A displays ancestry subgroups, while graph B represents specimen sites. Models DeepGEM and EAGLE are compared.
Figure 1. Survival Curves: Graphs display survival percentages vs. years after randomization for 'Overall survival' and 'Progression-free survival'. Data compares 'R-CHOP' and 'CHOP-RIT' treatments with numbers at risk shown below each graph.
Line graph titled 'Figure 1. Line Graph of Temporal Trends of Minimally Invasive Surgery (MIS)'. The Y axis indicates the Utilization rate (%), the X axis indicates Year from 2018 to 2023. The graph shows trends for Any MIS, Robotic assisted, and Conventional laparoscopic.
JAMA Oncology editorial: "Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better?" by Carmine Valenza text@1, text@2, text@3; Harold J. Burstein text@4 Published February 19, 2026.
Two graphs show cumulative incidence of progression from smoldering multiple myeloma. Graph A shows high vs not high risk based on AQUILA trial criteria, with high risk rising faster. Graph B shows high, intermediate and low risk for 2/20/2020 model risk groups.
Graph comparing "Tislelizumab plus chemotherapy" and "Placebo plus chemotherapy" over time (in months) versus OS (%). "Tislelizumab plus chemotherapy" shows a higher OS percentage than "Placebo plus chemotherapy" throughout the observed period.
Kaplan-Meier curves showing 10-year overall survival for sFT and sRP. sFT@1 starts at 100% and drops to roughly 57%. sRP@2 starts at 100% and ends around 72%. Years since salvage treatment are on the x-axis.
JAMA Oncology presents RCT: Bireociclib Plus Fulvestrant for Advanced Breast Cancer After Endocrine Progression. Population: 0 males, 305 females. Intervention: 305 patients randomized, details provided for "text@2" groups. Findings show prolonged PFS vs placebo.
Bar graph shows the burden reported in percentage. "Loss of ability to engage in activities that make life meaningful" is the highest at around 80%. "Inadequate control of other symptoms or concerns about it" is around 70%.
Kaplan-Meier graphs show overall survival and time to next treatment. Graph A shows overall survival probability decreasing over 48 months, with numbers at risk decreasing from 1480 to 46. Graph B shows the same trend for time to next treatment/death, decreasing from 1480 to 62.
Figure 1. Cumulative incidence plot of HPV-related cancer among males aged 9 to 26 years. The Y axis shows "Cumulative incidence per 100000 persons". The X axis shows "Years after index event". It plots vaccinated vs unvaccinated.
JAMA Oncology presents RCT: Bireociclib Plus Fulvestrant for Advanced Breast Cancer After Endocrine Progression. Population: 0 males, 305 females. Intervention: 305 patients randomized, details provided for "text@2" groups. Findings show prolonged PFS vs placebo.
Figure 2 shows cumulative incidence curves of cardiotoxic effects related to Trastuzumab based on CHIP status, from the SNUH cohort. Graphs A, B, and C display data from different cardiology groups, comparing CHIP(+) and CHIP(-) incidence over 2 years.